company background image
ORPH

Open OrphanAIM:ORPH Stock Report

Market Cap

UK£122.4m

7D

-1.0%

1Y

-13.9%

Updated

02 Dec, 2021

Data

Company Financials +
ORPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ORPH Stock Overview

Open Orphan plc operates as a pharmaceutical service and contract research company.

Price History & Performance

Summary of all time highs, changes and price drops for Open Orphan
Historical stock prices
Current Share PriceUK£0.20
52 Week HighUK£0.48
52 Week LowUK£0.17
Beta0.20
1 Month Change-2.22%
3 Month Change-23.85%
1 Year Change-13.91%
3 Year Changen/a
5 Year Changen/a
Change since IPO191.18%

Recent News & Updates

Feb 15
Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year

Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year

Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit...

Shareholder Returns

ORPHGB Life SciencesGB Market
7D-1.0%5.6%-2.2%
1Y-13.9%19.6%10.5%

Return vs Industry: ORPH underperformed the UK Life Sciences industry which returned 13.9% over the past year.

Return vs Market: ORPH underperformed the UK Market which returned 11.6% over the past year.

Price Volatility

Is ORPH's price volatile compared to industry and market?
ORPH volatility
ORPH Average Weekly Movement7.1%
Life Sciences Industry Average Movement7.0%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: ORPH is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ORPH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a179n/ahttps://www.openorphan.com

Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to Big Pharma, biotech, government, and public health organizations.

Open Orphan Fundamentals Summary

How do Open Orphan's earnings and revenue compare to its market cap?
ORPH fundamental statistics
Market CapUK£122.43m
Earnings (TTM)-UK£3.03m
Revenue (TTM)UK£36.13m

3.7x

P/S Ratio

-43.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORPH income statement (TTM)
RevenueUK£36.13m
Cost of RevenueUK£39.40m
Gross Profit-UK£3.27m
Expenses-UK£234.00k
Earnings-UK£3.03m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0045
Gross Margin-9.04%
Net Profit Margin-8.40%
Debt/Equity Ratio1.5%

How did ORPH perform over the long term?

See historical performance and comparison

Valuation

Is Open Orphan undervalued compared to its fair value and its price relative to the market?

6.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ORPH (£0.2) is trading above our estimate of fair value (£0.1)

Significantly Below Fair Value: ORPH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ORPH is unprofitable, so we can't compare its PE Ratio to the European Life Sciences industry average.

PE vs Market: ORPH is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORPH is overvalued based on its PB Ratio (6.1x) compared to the GB Life Sciences industry average (4.5x).


Future Growth

How is Open Orphan forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

184.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).

Earnings vs Market: ORPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ORPH's is expected to become profitable in the next 3 years.

Revenue vs Market: ORPH's revenue (19.2% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: ORPH's revenue (19.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ORPH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Open Orphan performed over the past 5 years?

72.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ORPH is currently unprofitable.

Growing Profit Margin: ORPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ORPH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ORPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORPH is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (77.1%).


Return on Equity

High ROE: ORPH has a negative Return on Equity (-13.94%), as it is currently unprofitable.


Financial Health

How is Open Orphan's financial position?


Financial Position Analysis

Short Term Liabilities: ORPH's short term assets (£24.6M) exceed its short term liabilities (£19.0M).

Long Term Liabilities: ORPH's short term assets (£24.6M) exceed its long term liabilities (£540.0K).


Debt to Equity History and Analysis

Debt Level: ORPH has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ORPH's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ORPH has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ORPH is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 59.2% per year.


Dividend

What is Open Orphan current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Open Orphan has no CEO, or we have no data on them.


Leadership Team

Experienced Management: ORPH's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: ORPH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Open Orphan plc's employee growth, exchange listings and data sources


Key Information

  • Name: Open Orphan plc
  • Ticker: ORPH
  • Exchange: AIM
  • Founded: NaN
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£122.431m
  • Shares outstanding: 670.86m
  • Website: https://www.openorphan.com

Number of Employees


Location

  • Open Orphan plc
  • 10-12 Alie Street
  • 2nd Floor
  • London
  • Greater London
  • E1 8DE
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 21:53
End of Day Share Price2021/12/02 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.